A new randomized controlled trial in the New England Journal of Medicine found that two sessions (three weeks apart) of 25 mg of psilocybin had at least as significant an impact on depressive symptoms as taking one of the most common SSRIs (escitalopram/Lexapro) daily for six weeks. The psilocybin group also reported fewer side effects and other positive emotional impacts. As the lead researcher put it, putting psilocybin head-to-head against the top antidepressant was a “brave and interesting” test to do as any such study has been lacking.
Access this study
